Abernethy Amy 4
4 · EQRx, Inc. · Filed Dec 21, 2021
Insider Transaction Report
Form 4
EQRx, Inc.EQRX
Abernethy Amy
Director
Transactions
- Exercise/Conversion
Class A Common Stock
2021-12-17+200,000→ 200,000 total - Other
Class A Common Stock
2021-12-17−200,000→ 0 total - Other
Common Stock
2021-12-17+200,000→ 200,000 total - Exercise/Conversion
Class B Common Stock
2021-12-17−200,000→ 0 total→ Class A Common Stock (200,000 underlying)
Footnotes (2)
- [F1]Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion").
- [F2]Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock.